Last updated: February 20, 2026
What is the current status of clinical trials for Capmatinib Hydrochloride?
Capmatinib Hydrochloride (INCMGA0012), a MET inhibitor developed by Novartis, aims to target MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC). As of early 2023, three major clinical trials are ongoing:
-
GEOMETRY mono-1 (NCT02871869): Phase 2 study assessing efficacy and safety in MET exon 14 skipping mutation-positive NSCLC. Results have demonstrated an overall response rate (ORR) of approximately 41% in evaluable patients, with a disease control rate (DCR) of 80%. The trial enrolled over 600 patients globally, with data reported in 2022.
-
NCT04395101: A phase 3 trial comparing Capmatinib versus chemotherapy in first-line treatment of MET exon 14 skipping NSCLC. Completion targeted for 2024, with interim analyses suggesting favorable efficacy outcomes.
-
NCT03711032: An exploratory trial investigating Capmatinib in combination with other targeted agents in MET-driven solid tumors. Preliminary data indicate evidence of activity in tumors beyond NSCLC.
Additional studies include investigations into pediatric malignancies and other MET-altered cancers, reflecting broadening interest in the drug's application.
How has market presence evolved for Capmatinib Hydrochloride?
Capmatinib received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2020 for adult patients with metastatic NSCLC harboring MET exon 14 skipping mutations. This marked its entry into the targeted oncology market. Market adoption has primarily depended on:
-
Regulatory approvals: After FDA approval, other regions, including the European Union and Japan, have initiated review processes. The European Medicines Agency (EMA) granted orphan drug designation in 2021, with a marketing authorization expected in late 2023.
-
Competitive landscape: The drug competes mainly with Tepotinib (Janssen), another MET inhibitor approved for similar indications, and with Caprelsa (Vandetanib) in broader MET-driven cancers.
-
Market size: The estimated prevalence of MET exon 14 skipping mutations in NSCLC is approximately 3-4%. The incidence of NSCLC with this mutation is estimated at 3,000 to 5,000 cases annually in the U.S. and EU markets combined, representing a limited but high-value segment.
-
Sales performance: In its initial launch year (2020), sales totaled approximately $150 million globally, with growth surpassing $200 million in 2022, driven by increased adoption and expanded indications.
What are future projections for Capmatinib Hydrochloride?
Market analysts forecast the following trends:
-
Market expansion: Increasing clinical evidence could lead to expanded approvals in indications beyond NSCLC, including other MET-driven tumors such as gastric cancers and gliomas. A broader label could magnify the target patient population to 20,000-30,000 annually in the U.S. and EU.
-
Revenue growth: Projected compound annual growth rate (CAGR) for global sales stands at approximately 12-15% over the next five years, reaching between $400-$600 million by 2028.
-
Competitive risks: Entry of newer, more selective MET inhibitors and combination regimens may impact market share. Patent expirations expected around 2030 could also introduce generic competition.
-
Manufacturing and pricing: Pricing strategies remain aggressively positioned around $10,000–$15,000 per month per patient, with potential discounts and biosimilar developments influencing profitability.
Summary table: Clinical trial milestones and market metrics
| Parameter |
Data |
| FDA approval date |
May 2020 |
| Approved indication |
MET exon 14 skipping NSCLC |
| Key clinical trial ORR |
41% in GEOMETRY mono-1 (NSCLC) |
| Estimated U.S. prevalence |
3,000–5,000 cases annually |
| Initial 2020 sales |
$150 million |
| Projected 2028 sales |
$400–$600 million |
| Expected patent expiration |
2030 |
Key Takeaways
Capmatinib Hydrochloride has established itself as a targeted therapy for MET exon 14 skipping NSCLC since FDA approval in 2020. Ongoing phase 3 trials and expanded indications could increase its market size substantially. Although competition and patent timelines pose challenges, sales growth is anticipated to sustain double-digit CAGR through 2028, driven by emerging clinical data and broader regulatory approvals.
FAQs
-
What is the primary indication for Capmatinib Hydrochloride?
It is approved for MET exon 14 skipping mutation-positive metastatic NSCLC.
-
Are there any other approved uses for Capmatinib?
Currently, approvals are limited to NSCLC. Expansion into other MET-driven cancers is under clinical investigation.
-
What are the main competitors for Capmatinib?
Tepotinib (Janssen) is the primary competitor with a similar approval profile.
-
How significant is the market opportunity outside NSCLC?
Potentially large if clinical trials confirm efficacy across other MET alterations, increasing eligible patients from thousands to tens of thousands annually.
-
When might biosimilars affect Capmatinib's market?
Patent expiry around 2030 could enable biosimilar development, impacting revenue and pricing.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves first targeted therapy for lung cancer with specific gene mutation. FDA news release.
[2] Novartis. (2023). Capmatinib clinical trial summaries. [Online] Available at: www.novartis.com
[3] GlobalData. (2023). Oncology therapeutics market report.
